Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed Mar 1, 2024
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2024-02-29$1.58/sh−8,661$13,684→ 706,932 total
Footnotes (1)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.